



AgiOS Pharmaceuticals Named 2014 World Economic Forum Technology Pioneer

August 27, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 27, 2013-- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), today announced that it has been selected as a [2014 World Economic Forum Technology Pioneer](#). Agios is one of 36 companies selected for this recognition for its potential to transform the future of business and society.

"We are incredibly honored to be recognized by the World Economic Forum along with 35 other companies that hope to impact the health and technology industries on a global scale," said David Schenkein, M.D., chief executive officer at Agios. "As a Technology Pioneer, we have the unique opportunity to engage with companies and individuals from around the world and share our novel approach to creating medicines that we believe can have a potentially transformative effect on patients."

Each year the World Economic Forum chooses a select number of Technology Pioneers from hundreds of applicants. Candidate companies are nominated by members, constituents and collaborators of the World Economic Forum and by the public. A selection committee comprised of top technology and innovation experts, academics and venture capitalists reviews all applications before making its recommendation to the World Economic Forum.

The Technology Pioneers will be recognized for their achievements in a ceremony on September 12, 2013 at the Annual Meeting of the New Champions 2013 in Dalian, People's Republic of China. The meeting is the foremost global business gathering in Asia, which brings together leaders from top-ranked multinationals and chief executive officers of dynamic and fast-growing companies. More information about the World Economic Forum's Technology Pioneers program along with the full list of winners can be found at <http://www.weforum.org/techpioneers>.

About Agios Pharmaceuticals, Inc.

AgiOS Pharmaceuticals is focused on discovering and developing novel drugs to treat cancer and rare metabolic genetic diseases (known as inborn errors of metabolism or IEMs) through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class lead product candidates in cancer metabolism and IEMs advancing toward the clinic. All Agios programs focus on genetically identified patient populations leveraging our knowledge of metabolism, biology and genomics. For more information, please visit our website at www.agios.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "hope," "believe," "expect" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to important risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs, including the risks described under the caption "Risk Factors" in Agios' Registration Statement on Form S-1 which was declared effective by the Securities and Exchange Commission (SEC) on July 23, 2013, and other filings that Agios may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Agios Pharmaceuticals, Inc.

AgiOS Pharmaceuticals, Inc.

Media Contact:

Dan Budwick, 973-271-6085

dan@purecommunicationsinc.com

or

Investor Contact:

Glenn Goddard

investors@agios.com